Option chain shows key data for Instil Bio's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Instil Bio.

Instil Bio (NASDAQ:TIL) Stock, Option Chain

Instil Bio

Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.

InstilBio courtesy photo

Analyst Color

Biotech

News

Upgrades

Health Care

Price Target

Analyst Ratings

Movers

Trading Ideas

General

BNTX

SMMT

Jefferies upgrades Instil Bio to &#34;Buy&#34; with a $52 target, anticipating significant growth for PD-(L)1xVEGF class and SYN2510&#39;s potential in cancer treatments.

Bullish Outlook On Instil Bio&#39;s Investigational Cancer Drug: Jefferies Sees Over 300% Stock Upside

movers image

Pre-Market Outlook

Markets

APLT

PGNY

VEEA

Steelcase Reports Weak Sales, Joins American Healthcare REIT And Other Big Stocks Moving Lower In Thursday&#39;s Pre-Market Session

FTEL

ITOS

MUFG

SEDG

SKYH

VSAT

Sky Harbour Group, SolarEdge Technologies And Other Big Stocks Moving Lower In Tuesday&#39;s Pre-Market Session

Instil Bio Inc

Till Capital Corp

Interface Inc

Listed Funds Trust Teucrium Agricultural Strategy No K-1 ETF

FlexShares Mornigstar US Market Factors Tilt Index Fund ETF

Earnings

Press Releases

Instil Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

Instil Bio and ImmuneOnco Announce License and Collaboration Agreement for Development of IMM2510, a Potentially Best-in-Class PD-L1xVEGF Bispecific Antibody, and IMM27M, a Novel Next-Generation Anti-CTLA-4 Antibody

Instil Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Instil Bio and ImmuneOnco Announce Global Registrational Strategy for PD-L1xVEGF Bispecific Antibody, SYN-2510/IMM2510, in Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer

Instil Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Instil Bio Announces Clinical Progress in China for IMM2510/SYN-2510, a Clinical-Stage PD-L1xVEGF Bispecific Antibody

Instil Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Achieve Life Sciences, Inc. - Common Shares

Achieve Life Sciences

Adaptimmune Therapeutics plc - American Depositary Shares

Adaptimmune Therapeutics

Agenus

Anixa Biosciences

Assembly Biosciences, Inc. - Common Stock

Assembly Biosciences

Biomea Fusion

Climb Bio

Corbus Pharmaceuticals Holdings, Inc. - Common Stock

Corbus Pharmaceuticals

Caribou Biosciences

CervoMed

Elicio Therapeutics

Galectin Therapeutics Inc. - Common Stock

Galectin Therapeutics

IGM Biosciences

I-MAB

Inozyme Pharma

Invivyd

Jasper Therapeutics, Inc. - Class A Common Stock

Jasper Therapeutics

Seres Therapeutics

MediciNova

OncoCyte

Senti Biosciences

Sutro Biopharma

TScan Therapeutics

Tenaya Therapeutics

Vor Biopharma

HC Wainwright & Co.

Jefferies

Baird

Truist Securities

Morgan Stanley

Comments

Instil Bio

Instil Bio (TIL) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell